EASL 2015: Grazoprevir/ Elbasvir Combo Cures 99% of Hepatitis C Patients with Chronic Kidney Disease
- Category: HCV Treatment
- Published on Thursday, 30 April 2015 00:00
- Written by Keith Alcorn
Merck's once-daily combination of grazoprevir and elbasvir cured hepatitis C in almost all people with advanced chronic kidney disease, researchers reported at theEuropean Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. The findings from the C-SURFER study are the first evidence that people with chronic kidney disease stand a very high chance of being cured using an interferon-free regimen, and will offer hope to a group of people with hepatitis C until now left behind by recent advances in antiviral treatment.